【Metagen Therapeutics, Inc.】 Metagen Therapeutics Passes AMED Stage-Gate Evaluation for MGT-006 Ulcerative Colitis Drug Development Program

2025.05.31

Metagen Therapeutics, Inc. has announced that its drug development program for MGT-006, a treatment for ulcerative colitis, has successfully passed the mid-term (stage-gate) evaluation under the “Strengthening Program for Pharmaceutical Startup Ecosystem (Drug Discovery Startup Public Call)” by the Japan Agency for Medical Research and Development (AMED).

◆Click the link for more details
Metagen Therapeutics Passes AMED Stage-Gate Evaluation for MGT-006 Ulcerative Colitis Drug Development Program